Gan & Lee Pharmaceuticals shines at ADA Scientific Sessions

Gan & Lee Pharmaceuticals, a prominent pharmaceutical company listed on the Shanghai Stock Exchange, has recently presented three abstracts highlighting their cutting-edge products at the American Diabetes Association's 84th Scientific Sessions. This event, taking place from June 21-24, 2024, in Orlando, Florida, will include live presentations of the featured studies on June 22. These abstracts will also be accessible on the Diabetes® journal website.

One of Gan & Lee's remarkable accomplishments is the creation of the first Chinese domestic insulin analog. Their insulin product range comprises six key offerings, including long-acting glargine injection (Basalin®) and fast-acting lispro injection (Prandilin™). Additionally, Gan & Lee has introduced medical devices like the reusable insulin injection pen (GanleePen) and disposable pen needle (GanleeFine®), which have obtained regulatory approvals in various markets.

In the recent Volume Based Procurement in China, Gan & Lee Pharmaceuticals emerged as a significant player, securing the second position overall and leading among domestic companies in the demand for insulin analogs. The company has also made notable progress in international markets, with its disposable pen needle receiving approvals from the US FDA and the EMA.

Looking to the future, Gan & Lee is dedicated to expanding its footprint in diabetes treatment and beyond. Their goal is to enrich their product portfolio by developing new chemical entities and biological drugs targeting metabolic diseases, cardiovascular conditions, and other therapeutic areas.

For further details, please reach out to BPRD@ganlee.com (Media) or BD@ganlee.com (Business Development).

Gan & Lee Pharmaceuticals' participation in the American Diabetes Association's Scientific Sessions underscores their commitment to advancing diabetes care through innovative products and solutions. With a focus on research and development, the company is poised to make significant contributions to the field of healthcare, benefiting patients worldwide.